JP2018503663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503663A5 JP2018503663A5 JP2017540230A JP2017540230A JP2018503663A5 JP 2018503663 A5 JP2018503663 A5 JP 2018503663A5 JP 2017540230 A JP2017540230 A JP 2017540230A JP 2017540230 A JP2017540230 A JP 2017540230A JP 2018503663 A5 JP2018503663 A5 JP 2018503663A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- hydrogen
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- -1 alkylphenyl ketone Chemical class 0.000 claims 2
- 125000006398 alkylpyrazinyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 0 **(CC1)CC(C(*2Cc3c(*)c(*)c(*)c(*)c3*)=O)=C1*1C2=*CC1 Chemical compound **(CC1)CC(C(*2Cc3c(*)c(*)c(*)c(*)c3*)=O)=C1*1C2=*CC1 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020195955A JP7579684B2 (ja) | 2015-01-30 | 2020-11-26 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2024122241A JP2024160257A (ja) | 2015-01-30 | 2024-07-29 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2025151932A JP2025186367A (ja) | 2015-01-30 | 2025-09-12 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109737P | 2015-01-30 | 2015-01-30 | |
| US62/109,737 | 2015-01-30 | ||
| US201562148844P | 2015-04-17 | 2015-04-17 | |
| US62/148,844 | 2015-04-17 | ||
| US201562233757P | 2015-09-28 | 2015-09-28 | |
| US62/233,757 | 2015-09-28 | ||
| PCT/US2016/015817 WO2016123571A1 (en) | 2015-01-30 | 2016-01-29 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195955A Division JP7579684B2 (ja) | 2015-01-30 | 2020-11-26 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503663A JP2018503663A (ja) | 2018-02-08 |
| JP2018503663A5 true JP2018503663A5 (https=) | 2019-03-07 |
| JP6802172B2 JP6802172B2 (ja) | 2020-12-16 |
Family
ID=56544438
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540230A Active JP6802172B2 (ja) | 2015-01-30 | 2016-01-29 | ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2020195955A Active JP7579684B2 (ja) | 2015-01-30 | 2020-11-26 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2024122241A Pending JP2024160257A (ja) | 2015-01-30 | 2024-07-29 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2025151932A Pending JP2025186367A (ja) | 2015-01-30 | 2025-09-12 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195955A Active JP7579684B2 (ja) | 2015-01-30 | 2020-11-26 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2024122241A Pending JP2024160257A (ja) | 2015-01-30 | 2024-07-29 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2025151932A Pending JP2025186367A (ja) | 2015-01-30 | 2025-09-12 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US9845324B2 (https=) |
| EP (4) | EP4516359A3 (https=) |
| JP (4) | JP6802172B2 (https=) |
| KR (3) | KR20250134216A (https=) |
| CN (2) | CN107427516B8 (https=) |
| AU (4) | AU2016211243B2 (https=) |
| BR (1) | BR112017016487B1 (https=) |
| CA (3) | CA2975476C (https=) |
| CY (1) | CY1123616T1 (https=) |
| DK (2) | DK3805222T3 (https=) |
| EA (1) | EA037552B1 (https=) |
| ES (2) | ES2839401T3 (https=) |
| FI (1) | FI3805222T3 (https=) |
| HR (2) | HRP20201949T1 (https=) |
| HU (2) | HUE070309T2 (https=) |
| IL (5) | IL312936A (https=) |
| LT (2) | LT3250208T (https=) |
| MA (2) | MA41434B1 (https=) |
| MD (2) | MD3805222T2 (https=) |
| MX (3) | MX379425B (https=) |
| PL (2) | PL3805222T3 (https=) |
| PT (2) | PT3250208T (https=) |
| RS (2) | RS66551B1 (https=) |
| SG (2) | SG10201803508WA (https=) |
| SI (2) | SI3250208T1 (https=) |
| SM (2) | SMT202000696T1 (https=) |
| WO (1) | WO2016123571A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016123571A1 (en) | 2015-01-30 | 2016-08-04 | Oncoceutics Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy |
| CN104860948B (zh) | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
| PL3408298T3 (pl) * | 2016-01-29 | 2025-03-31 | Oncoceutics, Inc. | Modulacja przez imiprydony receptora sprzężonego z białkiem g (gpcr) |
| WO2017151613A1 (en) | 2016-03-01 | 2017-09-08 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018031987A1 (en) | 2016-08-12 | 2018-02-15 | Nanjing Gator Meditech Company, Ltd. | Protein kinase regulators |
| US10172862B2 (en) * | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| US20200129596A1 (en) * | 2017-03-13 | 2020-04-30 | City Of Hope | m6A mRNA MODIFICATION IN CANCER TREATMENT |
| EP3589745A1 (en) * | 2018-04-11 | 2020-01-08 | Chemestmed Ltd. | A method of modulating the rna methylation |
| CN113631192B (zh) | 2019-03-26 | 2023-07-21 | 富士胶片株式会社 | 抑制乙型肝炎病毒蛋白产生的医药组合物、用于处置乙型肝炎的医药组合物及筛选方法 |
| BR112022015011A2 (pt) * | 2020-01-29 | 2022-09-20 | Corcept Therapeutics Inc | Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical |
| MX2023001576A (es) * | 2020-08-06 | 2023-05-09 | Eoetvoes Lorand Tudomanyegyetem | Síntesis de nuevos derivados de imipridona y su evaluación de su actividad anticáncerigena. |
| EP4223876A4 (en) | 2020-09-30 | 2025-12-10 | Fujifilm Corp | DOUBLE-STRANDED RNA THAT INHIBITS THE PRODUCTION OF A HEPATITIS B VIRUS PROTEIN, AND PHARMACEUTICAL COMPOSITION |
| KR20230118855A (ko) * | 2020-11-13 | 2023-08-14 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | IRE1α 억제제 및 이의 용도 |
| CN113100233B (zh) * | 2021-04-19 | 2022-02-08 | 中国农业科学院植物保护研究所 | 芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用 |
| CN115448921B (zh) * | 2021-06-08 | 2023-08-01 | 四川大学 | 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途 |
| CN115611896A (zh) * | 2021-07-16 | 2023-01-17 | 中国药科大学 | 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途 |
| WO2024218275A1 (en) * | 2023-04-20 | 2024-10-24 | Institut Gustave Roussy | Liquid and solid compositions of imipridone derivatives |
| CN119306718A (zh) * | 2023-07-11 | 2025-01-14 | 中科中山药物创新研究院 | 一种咪唑并吡啶并嘧啶酮类化合物及其制备方法和应用 |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
| WO2025250553A1 (en) * | 2024-05-28 | 2025-12-04 | Chimerix, Inc. | Solid state forms of imipridone derivative |
| EP4684834A1 (de) * | 2024-07-26 | 2026-01-28 | BRIU GmbH | Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung |
| CN119198986B (zh) * | 2024-11-28 | 2025-03-11 | 淄博高新技术产业开发区生物医药研究院 | 化药中n-亚硝基双氯芬酸基因毒杂质含量的分析方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2150062A1 (de) * | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
| US4642345A (en) | 1980-08-14 | 1987-02-10 | Mead Johnson & Company | 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| US7635690B2 (en) | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
| US7741285B2 (en) | 2001-11-13 | 2010-06-22 | Genentech, Inc. | APO-2 ligand/trail formulations |
| AU2003217961B2 (en) | 2002-03-08 | 2008-02-28 | Signal Pharmaceuticals, Llc | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| WO2004014909A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2004082570A2 (en) | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| EP1644536A4 (en) | 2003-07-08 | 2008-07-23 | Univ California | GENETIC MARKERS FOR RESPONSE TO ATYPIC ANTIPSYCHOTICS AND ANTIDEPRESSIVA AND METHOD FOR USE THEREOF |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| US20080221135A1 (en) | 2005-05-13 | 2008-09-11 | Bristol-Myers Squibb Company | Combination therapy |
| US8088895B2 (en) | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
| EP2350641B1 (en) | 2008-09-22 | 2014-09-24 | Amgen Inc. | A combination of a tnf alpha inhibitor, an iap inhibitor and a trail receptor agonist for use in treating cancer |
| NZ593343A (en) | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| US9724337B2 (en) | 2009-04-21 | 2017-08-08 | University Of Kentucky Research Foundation | AG-205 for the treatment of breast cancer |
| WO2011144622A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | 1h - imidazo [4, 5 - c] quinolines |
| US8735386B2 (en) | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
| EP2694678A2 (en) * | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
| US20130102595A1 (en) * | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| FI4335511T3 (fi) * | 2011-04-29 | 2026-01-29 | Penn State Res Found | Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2014160130A1 (en) * | 2013-03-13 | 2014-10-02 | Oncoceutics, Inc. | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
| WO2015073072A1 (en) * | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
| US9376437B2 (en) * | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| IL311202A (en) | 2013-11-15 | 2024-05-01 | Oncoceutics Inc | 7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-A] pyrido[3,4-E] pyrimidine-5(1H)one, its salts and methods Use |
| LT3662910T (lt) * | 2014-03-31 | 2024-12-27 | The Scripps Research Institute | Trail geno indukcijai skirtas farmakoforas |
| KR20150114239A (ko) * | 2014-04-01 | 2015-10-12 | 제일모직주식회사 | 내열성 및 착색성이 향상된 열가소성 수지 조성물 |
| WO2016123571A1 (en) * | 2015-01-30 | 2016-08-04 | Oncoceutics Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy |
| CN104860948B (zh) | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
-
2016
- 2016-01-29 WO PCT/US2016/015817 patent/WO2016123571A1/en not_active Ceased
- 2016-01-29 CN CN201680008476.7A patent/CN107427516B8/zh active Active
- 2016-01-29 KR KR1020257029332A patent/KR20250134216A/ko active Pending
- 2016-01-29 EP EP25152627.3A patent/EP4516359A3/en active Pending
- 2016-01-29 HU HUE20198062A patent/HUE070309T2/hu unknown
- 2016-01-29 IL IL312936A patent/IL312936A/en unknown
- 2016-01-29 HR HRP20201949TT patent/HRP20201949T1/hr unknown
- 2016-01-29 EP EP24210662.3A patent/EP4512483A3/en active Pending
- 2016-01-29 EA EA201791727A patent/EA037552B1/ru unknown
- 2016-01-29 LT LTEP16744237.5T patent/LT3250208T/lt unknown
- 2016-01-29 CA CA2975476A patent/CA2975476C/en active Active
- 2016-01-29 RS RS20250206A patent/RS66551B1/sr unknown
- 2016-01-29 BR BR112017016487-6A patent/BR112017016487B1/pt active IP Right Grant
- 2016-01-29 LT LTEP20198062.0T patent/LT3805222T/lt unknown
- 2016-01-29 HU HUE16744237A patent/HUE052821T2/hu unknown
- 2016-01-29 MD MDE20220113T patent/MD3805222T2/ro unknown
- 2016-01-29 CN CN202110266214.3A patent/CN113149985B/zh active Active
- 2016-01-29 RS RS20201566A patent/RS61243B1/sr unknown
- 2016-01-29 PT PT167442375T patent/PT3250208T/pt unknown
- 2016-01-29 JP JP2017540230A patent/JP6802172B2/ja active Active
- 2016-01-29 MD MDE20170317T patent/MD3250208T2/ro unknown
- 2016-01-29 HR HRP20250250TT patent/HRP20250250T1/hr unknown
- 2016-01-29 EP EP20198062.0A patent/EP3805222B1/en active Active
- 2016-01-29 SI SI201631003T patent/SI3250208T1/sl unknown
- 2016-01-29 MX MX2017009841A patent/MX379425B/es unknown
- 2016-01-29 IL IL295286A patent/IL295286B2/en unknown
- 2016-01-29 PL PL20198062.0T patent/PL3805222T3/pl unknown
- 2016-01-29 PT PT201980620T patent/PT3805222T/pt unknown
- 2016-01-29 CA CA3209515A patent/CA3209515A1/en active Pending
- 2016-01-29 CA CA3209519A patent/CA3209519A1/en active Pending
- 2016-01-29 FI FIEP20198062.0T patent/FI3805222T3/fi active
- 2016-01-29 SG SG10201803508WA patent/SG10201803508WA/en unknown
- 2016-01-29 MA MA41434A patent/MA41434B1/fr unknown
- 2016-01-29 DK DK20198062.0T patent/DK3805222T3/da active
- 2016-01-29 MA MA55402A patent/MA55402B1/fr unknown
- 2016-01-29 SI SI201631886T patent/SI3805222T1/sl unknown
- 2016-01-29 ES ES16744237T patent/ES2839401T3/es active Active
- 2016-01-29 MX MX2021001096A patent/MX2021001096A/es unknown
- 2016-01-29 SG SG11201706062TA patent/SG11201706062TA/en unknown
- 2016-01-29 PL PL16744237T patent/PL3250208T3/pl unknown
- 2016-01-29 KR KR1020237044537A patent/KR102856422B1/ko active Active
- 2016-01-29 SM SM20200696T patent/SMT202000696T1/it unknown
- 2016-01-29 IL IL288525A patent/IL288525B/en unknown
- 2016-01-29 SM SM20250087T patent/SMT202500087T1/it unknown
- 2016-01-29 DK DK16744237.5T patent/DK3250208T3/da active
- 2016-01-29 ES ES20198062T patent/ES3009132T3/es active Active
- 2016-01-29 KR KR1020177022405A patent/KR102618971B1/ko active Active
- 2016-01-29 EP EP16744237.5A patent/EP3250208B1/en active Active
- 2016-01-29 AU AU2016211243A patent/AU2016211243B2/en active Active
- 2016-02-22 US US15/049,613 patent/US9845324B2/en active Active
-
2017
- 2017-07-27 IL IL253689A patent/IL253689B/en active IP Right Grant
- 2017-07-28 MX MX2023000782A patent/MX2023000782A/es unknown
- 2017-11-20 US US15/817,896 patent/US10266533B2/en active Active
-
2019
- 2019-02-27 US US16/287,195 patent/US20190194201A1/en not_active Abandoned
-
2020
- 2020-04-22 IL IL274135A patent/IL274135B/en unknown
- 2020-11-26 JP JP2020195955A patent/JP7579684B2/ja active Active
- 2020-12-07 CY CY20201101158T patent/CY1123616T1/el unknown
- 2020-12-07 AU AU2020286168A patent/AU2020286168B8/en active Active
-
2021
- 2021-06-24 US US17/357,008 patent/US11976068B2/en active Active
-
2022
- 2022-09-06 AU AU2022228096A patent/AU2022228096A1/en not_active Abandoned
-
2024
- 2024-03-12 US US18/603,075 patent/US20240270746A1/en active Pending
- 2024-05-22 AU AU2024203421A patent/AU2024203421B2/en active Active
- 2024-07-29 JP JP2024122241A patent/JP2024160257A/ja active Pending
- 2024-12-12 US US18/979,567 patent/US20250109133A1/en active Pending
-
2025
- 2025-09-12 JP JP2025151932A patent/JP2025186367A/ja active Pending